Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas. NCCN Website. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 26 July 2019
2. Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A (2015) Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol 169(2):188–198. https://doi.org/10.1111/bjh.13273
3. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416. https://doi.org/10.1056/NEJMoa1214561
4. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD (2017) Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol 35(20):2260–2267. https://doi.org/10.1200/JCO.2017.72.2157
5. Dunleavy K, Noy A, Abramson J et al (2015) Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R. Blood 126(23):342. https://doi.org/10.1182/blood.V126.23.342
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献